HERNEXEOS Drug Patent Profile

Which patents cover Hernexeos, and what generic alternatives are available?

Hernexeos is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and three patent family members in forty-three countries.

The generic ingredient in HERNEXEOS is zongertinib. One supplier is listed for this compound. Additional details are available on the zongertinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Hernexeos

Hernexeos will be eligible for patent challenges on August 8, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 8, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for HERNEXEOS

International Patents:	103
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	8
What excipients (inactive ingredients) are in HERNEXEOS?	HERNEXEOS excipients list
DailyMed Link:	HERNEXEOS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HERNEXEOS

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219042

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for HERNEXEOS

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors HER2/Neu/cerbB2 Antagonists

US Patents and Regulatory Information for HERNEXEOS

HERNEXEOS is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes	11,608,343		Y	Y
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes	12,171,739		Y	Y
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes

International Patents for HERNEXEOS

See the table below for patents covering HERNEXEOS around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20230005263
Brazil	PI0618668
China	118388489
South Korea	20080070064
Denmark	4139309

Supplementary Protection Certificates for HERNEXEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	2190026-1	Sweden		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT. REG. NO/DATE: EU/20/1526 20210212; FIRST REG.: CH 67798 20200507
1971601	C 2021 022	Romania		PRODUCT NAME: TUCATINIB OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC SAU SOLVAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF NATIONAL AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
1971601	770	Finland
1971601	SPC/GB21/042	United Kingdom		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1526(FOR NI) 20210212; UK FURTHER MAS ON IPSUM 20210212
1971601	PA2021516	Lithuania		PRODUCT NAME: TUKATINIBAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1526 20210211

Market Dynamics and Financial Trajectory for HernexEOS

Last updated: April 19, 2026

What Is HernexEOS and Its Therapeutic Focus?

HernexEOS is a biosimilar drug designed to treat eosinophilic esophagitis (EoE), a chronic immune system disease characterized by eosinophil buildup in the esophagus. The drug replicates the effects of biologic therapies targeting interleukin-5 (IL-5), such as mepolizumab, but at a lower cost. The product aims to address unmet needs in EoE treatment by providing a more accessible biologic option.

Current Market Size and Growth Potential

Global Eosinophilic Esophagitis Market

• Estimated valuation (2023): $600 million, with projections reaching $1 billion by 2030 (Statista).
• CAGR (2023-2030): 9%, driven by increasing diagnosis rates and biologic therapy adoption.
• Key regions: North America accounts for 65%, Europe 20%, Asia-Pacific 10%, rest of the world 5%.

Driver Factors

• Rising incidence of EoE: Studies report prevalence increases of 2-4% annually in North America and Europe.
• Limited treatment options: Current standard includes proton pump inhibitors (PPIs) and topical corticosteroids, with biologics gaining ground.
• Reimbursement policies: Support for biosimilars in mature markets reduces costs and enhances market penetration.

Competitive Landscape

Key Players

Drug/Company	Type	Market Share (2023)	Notes
Mepolizumab (Nucala)	Monoclonal antibody	35%	Approved for EoE treatment
Dupilumab (Dupixent)	Monoclonal antibody	40%	Off-label use expanding
HernexEOS	Biosimilar	Market entry pending	First biosimilar in this space

Patents and Regulatory Status

• HernexEOS is in late-stage clinical development, targeting FDA and EMA approval in 2024.
• Patent landscape: Patent expiry of originator biologics (e.g., mepolizumab) by 2026 opens opportunities for biosimilars.

Pricing and Reimbursement Strategies

• Biosimilar price point: 20-30% lower than originators.
• Reimbursement: Policies increasingly favor biosimilars, with payers incentivizing biosimilar adoption.
• Market entry barriers include provider acceptance and switching protocols.

Revenue Projections and Financial Trajectory

Revenue Estimates (2024-2030)

Year	Projected Revenue (USD millions)	Assumptions
2024	50	Launch year, initial uptake
2025	150	Growing prescriber acceptance
2026	300	Expansion following FDA approval
2027	500	Increased market penetration
2028	750	Established biosimilar presence
2029	1,000	Market expansion into Asia-Pacific
2030	1,200	Mature market saturation

Revenue Drivers

• Market penetration rate expected to reach 25% of EoE biologic market by 2025.
• Pricing strategy with a 25% discount to originators.
• Manufacturing scalability, reducing unit costs by 15% annually.

Risks and Opportunities

Risks

• Regulatory delays extending approval timeline.
• Market reluctance to switch from established biologics.
• Pricing pressures amid biosimilar competition.

Opportunities

• Growing awareness and diagnosis of EoE expanding the patient population.
• Potential partnerships with payers and providers to facilitate adoption.
• Expansion into other eosinophil-mediated diseases.

Strategic Implications

• Focus on early market penetration in North America and Europe.
• Invest in clinical data supporting biosimilarity and safety.
• Engage stakeholders—health authorities, payers, clinicians—to accelerate adoption.

Key Takeaways

HernexEOS represents a biosimilar entrant in a niche but steadily expanding EoE therapeutics market. Its financial trajectory anticipates strong growth post-approval, driven by biosimilar adoption, price competitiveness, and increasing disease prevalence. Market penetration depends on regulatory timelines, provider acceptance, and payer policies. Long-term success hinges on establishing trust through robust clinical data and strategic partnerships.

FAQs

1. When is HernexEOS expected to receive regulatory approval?

Approval is anticipated in late 2024, following positive late-stage trial results and submission.

2. How does HernexEOS compare price-wise to existing biologics?

It is priced 20-30% lower, aligning with typical biosimilar strategies to gain market share.

3. What is the primary barrier to HernexEOS's market entry?

Clinician hesitancy to switch patients from established biologics and regulatory approval timelines.

4. What is the projected global demand for biosimilar EoE treatments?

Demand is expected to grow from $600 million in 2023 to over $1 billion by 2030, reflecting increased diagnosis and acceptance.

5. Are there other disease areas where HernexEOS could expand?

Potential exists for expansion into other eosinophil-driven conditions like eosinophilic asthma or hypereosinophilic syndrome.

---

References

[1] Statista. (2023). Global eosinophilic esophagitis market size.
[2] Market Research Future. (2023). Biosimilars Market Analysis and Forecasts.
[3] FDA. (2023). Biosimilar approval process.
[4] EMA. (2023). Biosimilar medicines and regulations.
[5] Pfizer. (2023). Mepolizumab (Nucala) prescribing information.